Inter Pharma Resultados de beneficios anteriores

Pasado controles de criterios 2/6

Inter Pharma ha aumentado sus beneficios a una tasa media anual de 2.9%, mientras que los beneficios de la industria de Personal Products han experimentado un crecimiento de 9.4% anual. Los ingresos han ido creciendo a una tasa media de 34.6% al año. La rentabilidad financiera de Inter Pharma es de 0.6%, y sus márgenes netos son de 0.6%.

Información clave

2.9%

Tasa de crecimiento de los beneficios

-4.1%

Tasa de crecimiento del BPA

Crecimiento de la industria Personal Products	3.7%
Tasa de crecimiento de los ingresos	34.6%
Rentabilidad financiera	0.6%
Margen neto	0.6%
Última actualización de beneficios	30 Sep 2024

Actualizaciones de resultados anteriores recientes

Recent updates

Desglose de ingresos y gastos

Cómo gana y gasta dinero Inter Pharma. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

SET:IP Ingresos, gastos y beneficios (THB Millions)
Fecha	Ingresos	Beneficios	Gastos G+A
30 Sep 24	1,807	11	624
30 Jun 24	1,809	20	607
31 Mar 24	1,809	27	597
31 Dec 23	1,799	51	568
30 Sep 23	1,815	92	555
30 Jun 23	1,775	108	540
31 Mar 23	1,739	128	513
31 Dec 22	1,534	119	458
30 Sep 22	1,385	130	390
30 Jun 22	1,226	125	339
31 Mar 22	1,016	118	284
31 Dec 21	921	105	267
30 Sep 21	760	68	253
30 Jun 21	626	63	230
31 Mar 21	526	56	202
31 Dec 20	447	53	187
30 Sep 20	408	62	162
30 Jun 20	390	57	155
31 Mar 20	389	56	156
31 Dec 19	376	43	157
30 Sep 19	371	28	175
30 Jun 19	365	27	176
31 Mar 19	343	24	169
31 Dec 18	318	30	152
31 Dec 17	248	16	120
31 Dec 16	125	16	59

Ingresos de calidad: IP tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio(0.6%) de IP son inferiores a los del año pasado (5.1%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de IP han crecido un 2.9% al año en los últimos 5 años.

Acelerando crecimiento: IP ha tenido un crecimiento negativo de los beneficios en el último año, por lo que no puede compararse con su media de 5 años.

Beneficios vs. Industria: IP tuvo un crecimiento negativo de los beneficios (-88.5%) durante el año pasado, lo que dificulta la comparación con la media de la industria Personal Products (-24.2%).

Inter Pharma Resultados de beneficios anteriores

Pasado controles de criterios 2/6

Información clave

Actualizaciones de resultados anteriores recientes

Second quarter 2024 earnings released: EPS: ฿0.006 (vs ฿0.019 in 2Q 2023)

First quarter 2024 earnings released: EPS: ฿0.042 (vs ฿0.066 in 1Q 2023)

Full year 2023 earnings: EPS and revenues miss analyst expectations

Third quarter 2023 earnings released: EPS: ฿0.037 (vs ฿0.09 in 3Q 2022)

Second quarter 2023 earnings released: EPS: ฿0.03 (vs ฿0.10 in 2Q 2022)

First quarter 2023 earnings released: EPS: ฿0.11 (vs ฿0.10 in 1Q 2022)

Recent updates

New minor risk - Share price stability

Second quarter 2024 earnings released: EPS: ฿0.006 (vs ฿0.019 in 2Q 2023)

Investor sentiment deteriorates as stock falls 26%

New minor risk - Share price stability

First quarter 2024 earnings released: EPS: ฿0.042 (vs ฿0.066 in 1Q 2023)

Investor sentiment deteriorates as stock falls 40%

Inter Pharma Public Company Limited Approves Dividend for the Year 2023, Payable on May 24, 2024

Now 20% overvalued

Dividend reduced to ฿0.035

Full year 2023 earnings: EPS and revenues miss analyst expectations

Inter Pharma Public Company Limited Proposes Dividend for the Year 2023, Payable on May 24, 2024

Less than half of directors are independent

Third quarter 2023 earnings released: EPS: ฿0.037 (vs ฿0.09 in 3Q 2022)

New minor risk - Market cap size

Consensus EPS estimates fall by 32%

Second quarter 2023 earnings released: EPS: ฿0.03 (vs ฿0.10 in 2Q 2022)

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 16%

Price target decreased by 9.7% to ฿18.10

Investor sentiment deteriorates as stock falls 25%

Inter Pharma Public Company Limited Announces CFO Changes

Investor sentiment deteriorates as stock falls 22%

First quarter 2023 earnings released: EPS: ฿0.11 (vs ฿0.10 in 1Q 2022)

Upcoming dividend of ฿0.18 per share at 1.6% yield

Price target decreased by 13% to ฿18.65

Inter Pharma Public Company Limited Announces Resignation of Terdkiat Prommool as Director

Consensus forecasts updated

Less than half of directors are independent

Second quarter 2022 earnings released: EPS: ฿0.10 (vs ฿0.086 in 2Q 2021)

Inter Pharma Public Company Limited announced that it has received THB 1.04314 billion in funding from Innobic LL Holding Company Limited

Inter Pharma Public Company Limited Approves Election of Directors

Inter Pharma Public Company Limited Announces Chief Financial Officer Changes

Consensus forecasts updated

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Price target increased to ฿26.00

High number of new and inexperienced directors

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Inter Pharma Public Company Limited Proposes Omission of Dividend Payment for 2021

Consensus forecasts updated

Consensus forecasts updated

Third quarter 2021 earnings released: EPS ฿0.088 (vs ฿0.064 in 3Q 2020)

Investor sentiment deteriorated over the past week

Second quarter 2021 earnings released: EPS ฿0.086 (vs ฿0.059 in 2Q 2020)

First quarter 2021 earnings released: EPS ฿0.091 (vs ฿0.048 in 1Q 2020)

Inter Pharma Public Company Limited Approves Cash Dividends for 2020, Payable on May 18, 2020

Revenue and earnings miss expectations

Full year 2020 earnings released: EPS ฿0.26 (vs ฿0.28 in FY 2019)

Inter Pharma Public Company Limited, Annual General Meeting, Apr 26, 2021

Inter Pharma Public Company Limited (SET:IP) entered into an agreement to acquire Certain Assets of Teva Pharma (Thailand) Co., Ltd. from Teva Pharma (Thailand) Co., Ltd. for THB 160 million.

Investor sentiment improved over the past week

Inter Pharma Public Company Replaces Amornsakdi Ketcharoon with Kamtorn Sila-On as an Independent Director, Audit Committee, Chairman of the Nomination and Remuneration Committee and Corporate Governance and Sustainable Development Committee, Effective February 8, 2021

New 90-day high: ฿19.70

Independent Director has left the company

Inter Pharma Public Company Limited Notifies the Resignation of Mr. Amornsakdi Ketcharoon from Independent Director, Audit Committee, Chairman of the Nomination and Remuneration Committee and Corporate Governance and Sustainable Development Committee ,Effective from January 31, 2021

Investor sentiment improved over the past week

New 90-day high: ฿14.00

New 90-day high: ฿13.60

Third quarter 2020 earnings released: EPS ฿0.09

Interpharma Public Company Limited Announces Director Changes

New 90-day high - ฿13.40

Earnings released

New 90-day high - ฿11.70

Desglose de ingresos y gastos

Historial de beneficios e ingresos

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Rentabilidad financiera

Rentabilidad económica

Rendimiento del capital invertido